Research Topics
| Peter B JahrlingSummaryAffiliation: Walter Reed Army Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpoxPeter B Jahrling
Headquarters, U S Army Research Institute of Infectious Diseases, Frederick, MD 21702, USA
Proc Natl Acad Sci U S A 101:15196-200. 2004..A more precise understanding of disease pathogenesis should provide targets for therapeutic intervention, to be used alone or in combination with inhibitors of variola virus replication...
Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaquesDouglas S Reed
Center for Aerobiological Sciences, U S Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, USA
Viral Immunol 17:390-400. 2004....- Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamilyLisa E Hensley
Pathology Division, US Army Medical Research Institute of Infectious Diseases USAMRIID, Attn MCMR UIP D, 1425 Porter Street, Fort Detrick, MD 21702 5011, USA
Immunol Lett 80:169-79. 2002..Identification of cytokine/chemokine, nitric oxide, and reactive oxygen species involvement in the observed filoviral pathogenesis may lend insight into the rational design of therapeutic countermeasures of filoviral pathogenesis... - Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cellsThomas W Geisbert
United States Army Medical Institute of Infectious Diseases, Fort Detrick, MD 21702 5011, USA
Am J Pathol 163:2371-82. 2003..Together, these data suggest that coagulation abnormalities associated with EBOV HF are not the direct result of EBOV-induced cytolysis of endothelial cells, and are likely triggered by immune-mediated mechanisms... - Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key eventThomas W Geisbert
Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA 21702 5011
J Infect Dis 188:1618-29. 2003..Thus, chemotherapeutic strategies aimed at controlling overexpression of TF may ameliorate the effects of EBOV hemorrhagic fever... - Towards a vaccine against Ebola virusThomas W Geisbert
Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702 5011, USA
Expert Rev Vaccines 2:777-89. 2003..This review takes a brief historic look at attempts to develop an efficacious vaccine, provides an overview of current vaccine candidates and highlights strategies that have the greatest potential for commercial development... - Smallpox and pan-orthopox virus detection by real-time 3'-minor groove binder TaqMan assays on the roche LightCycler and the Cepheid smart Cycler platformsDavid A Kulesh
Diagnostic Systems Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702 5011
J Clin Microbiol 42:601-9. 2004..The early detection of a smallpox outbreak is crucial whether the incident is an act of bioterrorism or an accidental occurrence... - Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interferenceThomas W Geisbert
United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702 5011, USA
J Infect Dis 193:1650-7. 2006..Here, we describe the development of a potential therapy for EBOV infection that is based on small interfering RNAs (siRNAs)... - Exotic emerging viral diseases: progress and challengesThomas W Geisbert
Virology Division, US Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Maryland 21702 5011, USA
Nat Med 10:S110-21. 2004..Of equal importance, these comparisons highlight critical gaps in our knowledge of these pathogens... - Development of a new vaccine for the prevention of Lassa feverThomas W Geisbert
Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA
PLoS Med 2:e183. 2005..Currently, there are no licensed vaccines for Lassa fever, and no experimental vaccine has completely protected nonhuman primates against a lethal challenge... - Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infectionThomas W Geisbert
United States Army Medical Institute of Infectious Diseases, Fort Detrick, MD 21702 5011, USA
Am J Pathol 163:2347-70. 2003..The sequence of pathogenetic events identified in this study should provide new targets for rational prophylactic and chemotherapeutic interventions... - Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infectionsThomas W Geisbert
Pathology Division, U S Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702 5011, USA
Virology 293:15-9. 2002..Taken together with in vivo observations that early deaths were not observed in animals immunized with various viral vectors expressing EBOV GP, it is unlikely that any EBOV-enhancing antibodies profoundly affected EBOV pathogenesis... - Real-time PCR assay to detect smallpox virusM Sofi Ibrahim
The United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702, USA
J Clin Microbiol 41:3835-9. 2003..The assay may be useful for the early detection of smallpox virus infections should such infections occur as a result of a deliberate or an accidental recurrence... - Evaluation in nonhuman primates of vaccines against Ebola virusThomas W Geisbert
U S Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702 5011, USA
Emerg Infect Dis 8:503-7. 2002..The disease observed in primates differed from that in rodents, suggesting that rodent models of EBOV may not predict the efficacy of candidate vaccines in primates and that protection of primates may require different mechanisms... - Inhibition of monkeypox virus replication by RNA interferenceAbdulnaser Alkhalil
United States Army Medical Research Institute of Infectious Diseases, Fort Detrick MD, 21702, USA
Virol J 6:188. 2009..These results emphasis the essential role of A6R gene in viral replication, and demonstrate the potential of RNAi as a therapeutic approach for developing oligonucleotide-based drug therapy for MPV and other orthopox viruses... - The International Code of Virus Classification and Nomenclature (ICVCN): proposal to delete Rule 3.41Jens H Kuhn
Integrated Research Facility at Fort Detrick IRF Frederick, Division of Clinical Research DCR, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, Fort Detrick, Frederick, MD, USA
Arch Virol 158:297-9. 2013..It is proposed to delete Rule 3.41 of the International Code of Virus Classification and Nomenclature, which requires the name of a virus taxon to precede the term for the taxonomic unit... - Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeysThomas W Geisbert
Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA
Lancet 362:1953-8. 2003..Here, we tested the notion that blockade of fVIIa/tissue factor is beneficial after infection with Ebola virus... - Detection and identification of Variola virus in fixed human tissue after prolonged archival storageRandal J Schoepp
Diagnostic Systems Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702 5011, USA
Lab Invest 84:41-8. 2004.... - Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family FiloviridaeJens H Kuhn
Integrated Research Facility at Fort Detrick IRF Frederick, Division of Clinical Research DCR, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, B 8200 Research Plaza, Fort Detrick, Frederick, MD, 21702, USA
Arch Virol 158:301-11. 2013..Most importantly, it would counter the increasing confusion in genetic variant naming due to the identification of ever more sequences through technological breakthroughs in high-throughput sequencing and environmental sampling... - Drug discovery technologies and strategies for Machupo virus and other New World arenavirusesSheli R Radoshitzky
United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA
Expert Opin Drug Discov 7:613-32. 2012.... - Commentary on Dr. Alan zelicoff's Analysis of the Aralsk outbreak (No. 4)Peter B Jahrling
U.S. Army Medical Research Institute of Infectious Disease, 1425 Porter Street, Frederick, MD 21702-5011, USA
Crit Rev Microbiol 29:171-2; discussion 183-90. 2003 - Clarification and guidance on the proper usage of virus and virus species namesJens H Kuhn
Integrated Research Facility at Fort Detrick IRF Frederick, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, B 8200 Research Plaza, Fort Detrick, Frederick, MD 21702, USA
Arch Virol 155:445-53. 2010.... - Countermeasures to the bioterrorist threat of smallpoxPeter B Jahrling
National Institute of Allergy and Infectious Diseases, National Institutes of Health, 6700 B Rockledge Drive, Bethesda, MD 20892 7609, USA
Curr Mol Med 5:817-26. 2005.... - Cynomolgus macaque as an animal model for severe acute respiratory syndromeJames V Lawler
Infectious Diseases Department, National Naval Medical Center, Bethesda, Maryland, United States of America
PLoS Med 3:e149. 2006.... - Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPsNancy J Sullivan
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
PLoS Med 3:e177. 2006..GP can exert cytopathic effects on transfected cells in vitro, and multiple GP forms have been identified in nature, raising the question of which would be optimal for a human vaccine... - The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic feverKathleen H Rubins
Department of Microbiology and Immunology, 299 Campus Dr, Stanford University School of Medicine, Stanford, California 94305, USA
Genome Biol 8:R174. 2007..Infection with Ebola virus (EBOV) causes a fulminant and often fatal hemorrhagic fever. In order to improve our understanding of EBOV pathogenesis and EBOV-host interactions, we examined the molecular features of EBOV infection in vivo... - Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primatesPeter B Jahrling
Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, MD, USA
J Infect Dis 196:S400-3. 2007..These data cast further doubt on the value of passive immunotherapy for the treatment of EBOV infection... - Pathologic findings associated with delayed death in nonhuman primates experimentally infected with Zaire Ebola virusThomas Larsen
Pathology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA
J Infect Dis 196:S323-8. 2007..We suggest that treatment extended the time course of the disease and permitted the virus to infect tissues not usually affected in the typical model... - Neutralizing antibody fails to impact the course of Ebola virus infection in monkeysWendelien B Oswald
Departments of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California, United States of America
PLoS Pathog 3:e9. 2007..It appears that Ebola virus has a mechanism of infection propagation in vivo in macaques that is uniquely insensitive even to high concentrations of neutralizing antibody... - Analysis of the expressed heavy chain variable-region genes of Macaca fascicularis and isolation of monoclonal antibodies specific for the Ebola virus' soluble glycoproteinChris Druar
Cangene Corporation, 3404 American Drive, Mississauga, Ontario L4V 1T4, Canada
Immunogenetics 57:730-8. 2005..In summary, the study provides new insight into the M. fascicularis V region gene repertoire and further supports the idea that macaque-derived mAbs may be of therapeutic value to humans... - Virulence differences between monkeypox virus isolates from West Africa and the Congo basinNanhai Chen
Department of Molecular Microbiology and Immunology, Saint Louis University Health Sciences Center, M432, St. Louis, MO 63104, USA
Virology 340:46-63. 2005..The analysis identified D10L, D14L, B10R, B14R, and B19R as possible virulence genes, with D14L (ortholog of vaccinia complement protein) as a leading candidate... - Detection of antibodies against the four subtypes of ebola virus in sera from any species using a novel antibody-phage indicator assayFelix Meissner
Department of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
Virology 300:236-43. 2002..The assay is designed to be both simple and economical to enable its use in the field... - Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primatesNancy J Sullivan
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg. 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, Maryland 20892-3005, USA
Nature 424:681-4. 2003..This accelerated vaccine provides an intervention that may help to limit the epidemic spread of Ebola, and is applicable to other viruses... - Smallpox research activities: U.S. interagency collaboration, 2001James W Leduc
Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Emerg Infect Dis 8:743-5. 2002 - Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirusBoyd Yount
Department of Epidemiology and Microbiology, University of North Carolina, Chapel Hill, NC 27599-7435, USA
Proc Natl Acad Sci U S A 100:12995-3000. 2003.... - Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypoxPatricia L Earl
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-0445, USA
Nature 428:182-5. 2004.... - Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibodyPaul W H I Parren
Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
J Virol 76:6408-12. 2002..KZ52 is a promising candidate for immunoprophylaxis of Ebola virus infection... - Interferon-beta 1a and SARS coronavirus replicationLisa E Hensley
Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702, USA
Emerg Infect Dis 10:317-9. 2004..Here, we report that recombinant human interferon-beta 1a potently inhibits SARS coronavirus replication in vitro... - The host response to smallpox: analysis of the gene expression program in peripheral blood cells in a nonhuman primate modelKathleen H Rubins
Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA
Proc Natl Acad Sci U S A 101:15190-5. 2004..These results provide a detailed picture of the host transcriptional response during smallpox infection, and may help guide the development of diagnostic, therapeutic, and prophylactic strategies... - Hemorrhagic fever occurs after intravenous, but not after intragastric, inoculation of rhesus macaques with lymphocytic choriomeningitis virusIgor S Lukashevich
Institute of Human Virology, University of Maryland, Biotech Center, Baltimore, Maryland 21201, USA
J Med Virol 67:171-86. 2002..Pathological signs of the primate i.v. infection differ significantly from guinea pig arenavirus infections and make this a superior model for human viral hemorrhagic disease... - Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic feverLisa E Hensley
Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA
J Infect Dis 196:S390-9. 2007..The aim of this study was to test the efficacy of rhAPC as a potential treatment for ZHF... - Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg virusesSteven M Jones
Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba R3E 3R2, Canada
Nat Med 11:786-90. 2005..No evidence of EBOV or MARV replication was detected in any of the protected animals after challenge. Our data suggest that these vaccine candidates are safe and highly efficacious in a relevant animal model... - Hemorrhagic fever viruses as biological weapons: medical and public health managementLuciana Borio
Johns Hopkins Center for Civilian Biodefense Strategies, Johns Hopkins Schools of Medicine and Public Health, 111 Market Pl, Suite 830, Baltimore, MD 21202, USA
JAMA 287:2391-405. 2002..To develop consensus-based recommendations for measures to be taken by medical and public health professionals if hemorrhagic fever viruses (HFVs) are used as biological weapons against a civilian population... - Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigsJenny L Mellquist-Riemenschneider
Department of Molecular Virology, Virology Division, Division U.S. Army Medical Research Institute of Infectious Diseases, 1301 Ditto Ave, Ft. Detrick, Frederick 21702, MD, USA
Virus Res 92:187-93. 2003..These data indicate that a vaccine approach that was effective for MARV is not effective for EBOV in guinea pigs... - Trigger events: enviroclimatic coupling of Ebola hemorrhagic fever outbreaksJorge E Pinzon
Biospheric Sciences Branch, Laboratory for Terrestrial Physics, National Aeronautics and Space Administration Goddard Space Flight Center, Greenbelt, MD 20771, USA
Am J Trop Med Hyg 71:664-74. 2004..These findings suggest specific directions to help understand the sylvatic cycle of the virus and may provide early warning tools to detect possible future outbreaks of this enigmatic disease... - Dynamics of oliveros virus infection in rodents in central ArgentinaJames N Mills
Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
Vector Borne Zoonotic Dis 7:315-23. 2007..Infection may have been associated with scars, which were also approximately equally distributed among male and female Necromys... - Panmicrobial oligonucleotide array for diagnosis of infectious diseasesGustavo Palacios
Columbia University, New York, New York 10032, USA
Emerg Infect Dis 13:73-81. 2007.... - MassTag polymerase chain reaction for differential diagnosis of viral hemorrhagic feverGustavo Palacios
Columbia University, New York, New York 10032, USA
Emerg Infect Dis 12:692-5. 2006..We describe a diagnostic system for rapid, multiplex polymerase chain reaction identification of 10 different causes of viral hemorrhagic fevers... - Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessmentKathleen M Daddario-DiCaprio
Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA
Lancet 367:1399-404. 2006..We aimed to test the efficacy of a replication-competent vaccine based on attenuated recombinant vesicular stomatitis virus (rVSV), as a postexposure treatment for MARV haemorrhagic fever... - Ebola and Marburg viruses: pathogenesis and development of countermeasuresLisa E Hensley
Virology Division, U.S. Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702-5011, USA
Curr Mol Med 5:761-72. 2005..In addition, substantial progress has been made in developing recombinant vaccines against these viruses... - Viral hemorrhagic feversAileen M Marty
Battelle Memorial Institute, Suite 601, 1550 Crystal Drive, Arlington, VA 22202 4172, USA
Clin Lab Med 26:345-86, viii. 2006..While significant progress has been made over the last several years in dissecting out the molecular biology and pathogenesis of the HF viruses, there are currently no vaccines or drugs licensed available for most of the VHFs...